Skip to main content

Rosetta Awarded Israeli Grant to Develop microRNA-targeting Cancer Drug

Premium

Rosetta Genomics this week announced that it has been awarded a $200,000 grant along with Ramot, Tel Aviv University’s technology-transfer company, to develop microRNA-targeting cancer drugs.

According to the company, the initial focus of the alliance will be on developing a mimic of miR-34a delivered using a polymeric carrier. The miRNA is a tumor suppressor downregulated in a variety of cancers, Rosetta said.

Notably, a miR-34a mimic developed by Mirna Therapeutics is already in the clinic as a cancer treatment (GSN 5/2/2013).

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.